글로벌 효소 연결 면역점 분석 시장 – 2029년까지의 산업 동향 및 예측

효소 연결 면역점 분석 시장 분석 및 규모

Globocan 2020에 따르면 전 세계적으로 약 9,958,133건의 암 관련 사망자가 발생했으며, 약 19,292,789건의 새로운 암 사례가 확인되었습니다. 또한 국제암연구소(IARC)는 2040년까지 전 세계적으로 1,630만 건의 암 관련 사망자와 2,750만 건의 새로운 암 사례가 발생할 것으로 예측합니다. 효소 연결 면역점 검사 수요는 암 사례 수의 증가로 인해 증가할 것으로 예상됩니다.

Data Bridge Market Research는 2021년에 4억 9,377만 달러였던 효소 연결 면역점 검사 시장이 2029년까지 7억 1,193만 달러로 급증할 것이며, 2022년부터 2029년까지의 예측 기간 동안 4.68%의 CAGR을 보일 것으로 분석했습니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 시장 세그먼트, 지리적 범위, 시장 참여자, 시장 시나리오와 같은 시장 통찰력 외에도 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석, 규제 프레임워크가 포함되어 있습니다.

효소 연결 면역점 검사 시장 범위 및 세분화

Market Definition

The enzyme linked immunospot (ELISpot) assays is a fundamental tool in cellular immunology, providing both quantitative and qualitative information on cellular cytokine responses to defined antigens. In order to identify CD8+ T cells that are specific to an epitope, the enzyme-linked immunospot (ELISPOT) assays is a sensitive immunologic technique that measures cytokine release on a single-cell basis. A putative antigenic peptide is delivered to CD8+ T lymphocytes via MHC-I on antigen-presenting cells (APCs). ELISpot assays are quicker, more trustworthy, and less expensive than other functional assays (e.g., ICS). They are especially well suited for screenings because of their great sensitivity and simplicity of use.

Enzyme Linked Immunospot Assays Market Dynamics

Drivers

• Increase in diagnostic technologies

According to the World Health Organization, over 354 million individuals worldwide are estimated to have hepatitis B or C infections in 2020. The need for a diagnosis arise due to the rising occurrence of infectious diseases. The expansion of the market is related to the rising use of cutting-edge diagnostic technologies for illness screening, such as enzyme linked immunosorbent assays.

• Rising chronic diseases

According to the World Health Organization's December 2020 report, the major chronic diseases currently account for over 60% of all fatalities and 43% of the burden of disease globally. By 2020, it is anticipated that their share of global morbidity and mortality will reach 60% and 73 percent, respectively. Additionally, chronic diseases account for 79 percent of mortality in underdeveloped nations. Additionally, market expansion is anticipated to be fuelled by technological advancements in assay kits and analyzers for enzyme linked immunosorbent assay.

• Rising healthcare expenditure

According to the Center for Disease Control and Prevention 2021, the leading causes of mortality and disability in the United States are chronic diseases like heart disease, cancer, and diabetes. Additionally, they are primarily responsible for the USD 3.8 trillion in annual healthcare expenditures in the US. As a result of increasing healthcare costs and the incidence of chronic diseases, the market is expected to rise throughout the forecast period.

Opportunities

• Increase in the number of research and development activities 

The market's growth is fuelled by rising number of patients with infectious diseases around the world, the proliferation of innovative and novel products, and the use of advanced technology for multiple diagnosis are expected to boost the growth of the enzyme linked immunospot assays market.

On the other hand, throughout the forecast period, the market will expand due to the launch of numerous medications that will further boost potential of the market.

Restraints/Challenges

On the other hand, the easy availability of alternative methods will obstruct the market's growth rate.

This enzyme linked immunospot assays market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the enzyme linked immunospot assays market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Enzyme Linked Immunospot Assays Market

Enzyme-linked immunosorbent assay (ELISA) demand has surged due to the COVID-19 all over the world. The main cause of this is the rise in infection rates, which increased the demand for accurate diagnosis. Data from the National Center for Biotechnology Information (NCBI) Journal in 2020 show that SARS-CoV-2 can be accurately detected using the enzyme-linked immunosorbent assay (ELISA). The demand for more affordable and accurate diagnosis in order to receive the right treatment is anticipated to fuel market expansion.

Global Enzyme Linked Immunospot Assays Market Scope

The enzyme linked immunospot assays market is segmented on the basis of test type and application. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Test Type

• Sandwich ELISA
• Indirect ELISA
• Multiple and Portable ELISA
• Competitive ELISA

 Application

• Immunology
• Inflammation
• Infectious Diseases
• Cancer
• Protein Quantitation
• Other

Enzyme Linked Immunospot Assays Market Regional Analysis/Insights

The enzyme linked immunospot assays market is analysed and market size insights and trends are provided by country, test type and application as referenced above.

The countries covered in the enzyme linked immunospot assays market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the enzyme linked immunospot assays market owing to the emergence in the abundance of businesses, developed healthcare foundation, and the extent of communicable disorders and the improvement of several innovative commodities.

아시아 태평양 지역은 인프라 개발과 진단 도구 도입과 더불어 환자 인구 증가로 인해 2022년부터 2029년까지 가장 높은 성장률을 기록할 것으로 예상됩니다.

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 다운스트림 및 업스트림 가치 사슬 분석, 기술 트렌드 및 포터의 5가지 힘 분석, 사례 연구와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 몇 가지 포인터입니다. 또한 글로벌 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 국내 관세 및 무역 경로의 영향은 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.

경쟁 환경 및 효소 연결 면역점 검사 시장 점유율 분석

효소 결합 면역점 검사 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우위가 있습니다. 위에 제공된 데이터 포인트는 효소 결합 면역점 검사 시장과 관련된 회사의 초점에만 관련이 있습니다.

효소 연결 면역점 검사 시장에서 활동하는 주요 업체는 다음과 같습니다.

• Thermo Fisher Scientific Inc. (미국)
• BD(미국)
• Bio-Rad Laboratories, Inc. (미국)
• bioMérieux (프랑스)
• 머크 KGaA(독일)
• 레이바이오텍 라이프 주식회사(미국)
• R&D Systems, Inc. (미국)
• AESKU.GROUP GmbH & Co. KG(독일)
• Eurofins Scientific(룩셈부르크)
• Biogenuix(인도)
• F. 호프만-라 로슈 유한회사(스위스)
• 애벗(미국)
• 다나허(미국)
• 시스멕스 주식회사(일본)
• 퍼킨엘머 주식회사(미국)
• Agilent Technologies Inc. (미국)

SKU-53850